medinfoАктуальные проблемы теоретической и клинической медициныActual Problems of Theoretical and Clinical Medicine2790-12892790-1297Казахстанско-Российский медицинский университет10.24412/2790-1289-2023-2-25-31medinfo-320Research ArticleКЛИНИЧЕСКИЙ СЛУЧАЙCLINICAL CASEПоражение почек при подагре (клиническое наблюдение)Kidney damage in gout (clinical observation)https://orcid.org/0000-0003-0379-3109ПоляковаВ. В.PoliakovaV.

Валентина Викторовна Полякова, кандидат медицинских наук, доцент

Санкт-Петербург

Valentina Poliakova, Candidate of Medical Sciences, Associate Professor

St. Petersburg

valentina.poljakova@szgmu.ruКуницкаяН. А.KunitskayaN.

Наталья Александровна Куницкая, доктор медицинских наук, профессор

Санкт-Петербург

Nataliya Kunitskaya, Doctor of Medical Sciences, Professor

St. Petersburg

scvssd@yandex.ruhttps://orcid.org/0000-0003-0873-8264ЛеонтьеваН. В.LeontevaN.

Наталия Владимировна Леонтьева, доктор медицинских наук, профессор

Санкт-Петербург

Natalia Leonteva, MD, Professor

St. Petersburg

leontyevanv@mail.ru«СЗГМУ имени И.И. Мечникова» МЗ РФРоссия«North-Western State Medical University named after I. I. Mechnikov»Russian Federation202312082023022531Copyright © Полякова В.В., Куницкая Н.А., Леонтьева Н.В., 20232023Полякова В.В., Куницкая Н.А., Леонтьева Н.В.Poliakova V., Kunitskaya N., Leonteva N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://kazrosmedjournal.krmu.edu.kz/jour/article/view/320

Подагра – заболевание, характеризующееся гиперурикемией и отложением в тканях организма кристаллов уратов в форме моноурата натрия. Причиной заболевания являются избыточное образование мочевой кислоты и уменьшение её выведения почками, что приводит к повышению ее концентрации в крови и тканях. Клинически подагра проявляется рецидивирующим острым артритом и образованием подагрических узлов - тофусов. Наряду с артритом одним из основных клинических проявлений подагры является поражение почек. Чаще заболевание встречается у мужчин, однако в последнее время возрастает распространённость заболевания среди женщин. С возрастом распространённость подагры увеличивается. Несмотря на азбучность клинических проявлений ведение таких пациентов представляет определенные сложности.

Gout is a disease characterized by hyperuricemia and the deposition of urate crystals in the body tissues in the form of sodium monourate or uric acid. The cause of the disease is the excessive formation of uric acid and a decrease in its excretion by the kidneys, which leads to an increase in its concentration in the blood. Clinically, gout is manifested by recurrent acute arthritis and the formation of gouty nodes - tophi. Along with arthritis, one of the main clinical manifestations of gout is kidney damage. More often the disease occurs in men, but recently the prevalence of the disease among women has increased, with age the prevalence of gout increases. Despite the elementary nature of the clinical manifestations of gout, its diagnosis is still very difficult. On a clinical example, we consider typical errors that occur in the diagnosis of this pathology.

подаграповреждение почекклинический примерфебуксостатgoutkidney damageclinical examplefebuxostatОтсутствуетAbsentReferencesShin D.H. To treat or not to treat asymptomatic hyperuricemia in chronic kidney disease. Kidney Res Clin Pract 38: 257–259, 2019.Shin D.H. To treat or not to treat asymptomatic hyperuricemia in chronic kidney disease. Kidney Res Clin Pract 38: 257–259, 2019.Robinson P.C., Dalbeth N. Febuxostat for the treatment of hyperuricaemia in gout. Expert Opin Pharmacother. 2018 Aug;19(11):1289-1299.Robinson P.C., Dalbeth N. Febuxostat for the treatment of hyperuricaemia in gout. Expert Opin Pharmacother. 2018 Aug;19(11):1289-1299.Tsai C.W., Lin S.Y., Kuo C.C., Huang C.C. Serum uric acid and progression of kidney disease: a longitudinal analysis and mini-review. PLoS One 12: e0170393, 2017.Tsai C.W., Lin S.Y., Kuo C.C., Huang C.C. Serum uric acid and progression of kidney disease: a longitudinal analysis and mini-review. PLoS One 12: e0170393, 2017.Turner J.E., Becker M., Mittrücker H.W., Panzer U. Tissue-resident lymphocytes in the kidney. J Am Soc Nephrol 29: 389 – 399, 2018.Turner J.E., Becker M., Mittrücker H.W., Panzer U. Tissue-resident lymphocytes in the kidney. J Am Soc Nephrol 29: 389 – 399, 2018.Xiao J., Fu C., Zhang X., Zhu D., Chen W., Lu Y., Ye Z. Soluble monosodium urate, but not its crystal, induces toll like receptor 4-dependent immune activation in renal mesangial cells. Mol Immunol 66: 310 – 318, 2015.Xiao J., Fu C., Zhang X., Zhu D., Chen W., Lu Y., Ye Z. Soluble monosodium urate, but not its crystal, induces toll like receptor 4-dependent immune activation in renal mesangial cells. Mol Immunol 66: 310 – 318, 2015.Xu X., Hu J., Song N., Chen R., Zhang T., Ding X. Hyperuricemia increases the risk of acute kidney injury: a systematic review and meta-analysis. BMC Nephrol 18: 27, 2017.Xu X., Hu J., Song N., Chen R., Zhang T., Ding X. Hyperuricemia increases the risk of acute kidney injury: a systematic review and meta-analysis. BMC Nephrol 18: 27, 2017.Oh T.R., Choi H.S., Kim C.S., Bae E.H., Ma S.K., Sung S.A., Kim Y.S., Oh K.H., Ahn C., Kim S.W. Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study. Sci Rep 9: 6681, 2019.Oh T.R., Choi H.S., Kim C.S., Bae E.H., Ma S.K., Sung S.A., Kim Y.S., Oh K.H., Ahn C., Kim S.W. Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study. Sci Rep 9: 6681, 2019.Ejaz A.A., Johnson R.J., Shimada M., et al. The role of uric acid in acute kidney injury. NEPHRON. 2019;142(4):275–283. doi: 10.1159/000499939.Ejaz A.A., Johnson R.J., Shimada M., et al. The role of uric acid in acute kidney injury. NEPHRON. 2019;142(4):275–283. doi: 10.1159/000499939.Zhou F., Yu G., Wang G., et al. Association of serum uric acid levels with the incident of kidney disease and rapid eGFR decline in Chinese individuals with eGFR > 60 mL/min/1.73 m<sup>2</sup> and negative proteinuria. Clinical and Experimental Nephrology. 2019;23(7):871–879. doi: 10.1007/s10157-019-01705-w.Zhou F., Yu G., Wang G., et al. Association of serum uric acid levels with the incident of kidney disease and rapid eGFR decline in Chinese individuals with eGFR > 60 mL/min/1.73 m<sup>2</sup> and negative proteinuria. Clinical and Experimental Nephrology. 2019;23(7):871–879. doi: 10.1007/s10157-019-01705-w.Hasegawa J., Maejima I., Iwamoto R., Yoshimori T. Selective autophagy: Lysophagy. Methods. 2015; 75:128–132. doi: 10.1016/j.ymeth.2014.12.014Hasegawa J., Maejima I., Iwamoto R., Yoshimori T. Selective autophagy: Lysophagy. Methods. 2015; 75:128–132. doi: 10.1016/j.ymeth.2014.12.014Fan S., Zhang P., Wang A. Y., et al. Hyperuricemia and its related histopathological features on renal bi- opsy. BMC Nephrology. 2019;20(1): p. 95. doi: 10.1186/s12882-019-1275-4.Fan S., Zhang P., Wang A. Y., et al. Hyperuricemia and its related histopathological features on renal bi- opsy. BMC Nephrology. 2019;20(1): p. 95. doi: 10.1186/s12882-019-1275-4.Schlee S., Bollheimer L. C., Bertsch T., Sieber C.C., Harle P. Crystal arthritides-gout and calcium pyrophosphate arthritis. Zeitschrift Fur Gerontologie Und Geriatrie. 2018;51(5):579–584. doi: 10.1007/s00391-017-1198-2Schlee S., Bollheimer L. C., Bertsch T., Sieber C.C., Harle P. Crystal arthritides-gout and calcium pyrophosphate arthritis. Zeitschrift Fur Gerontologie Und Geriatrie. 2018;51(5):579–584. doi: 10.1007/s00391-017-1198-2Yang L., Chang B., Guo Y., Wu X., Liu L. The role of oxidative stress-mediated apoptosis in the pathogenesis of uric acid nephropathy. Renal Failure. 2019;41(1):616–622. doi: 10.1080/0886022X.2019.1633350Yang L., Chang B., Guo Y., Wu X., Liu L. The role of oxidative stress-mediated apoptosis in the pathogenesis of uric acid nephropathy. Renal Failure. 2019;41(1):616–622. doi: 10.1080/0886022X.2019.1633350Yu M.A., Sanchez-Lozada L.G., Johnson R.J., Kang D.H. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. Journal of Hypertension. 2010;28(6):1234–1242.Yu M.A., Sanchez-Lozada L.G., Johnson R.J., Kang D.H. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. Journal of Hypertension. 2010;28(6):1234–1242.Song X., Sun Z., Chen G., et al. Matrix stiffening induces endothelial dysfunction via the TRPV4/microRNA-6740/endothelin-1 mechanotransduction pathway. Acta Biomaterialia. 2019; 100:52–60. doi: 10.1016/j.actbio.2019.10.013Song X., Sun Z., Chen G., et al. Matrix stiffening induces endothelial dysfunction via the TRPV4/microRNA-6740/endothelin-1 mechanotransduction pathway. Acta Biomaterialia. 2019; 100:52–60. doi: 10.1016/j.actbio.2019.10.013Johnson R. J., Nakagawa T., Jalal D., Sanchez-Lozada L. G., Kang D.-H., Ritz E. Uric acid and chronic kidney disease: which is chasing which? Nephrology, dialysis, transplantation. 2013; 28(9):2221–2228. doi: 10.1093/ndt/gft029Johnson R. J., Nakagawa T., Jalal D., Sanchez-Lozada L. G., Kang D.-H., Ritz E. Uric acid and chronic kidney disease: which is chasing which? Nephrology, dialysis, transplantation. 2013; 28(9):2221–2228. doi: 10.1093/ndt/gft029Lisa K Stamp, Tony R Merriman, Jasvinder A Singh. Expert opinion on emerging urate-lowering therapies. Expert Opin Emerg Drugs. 2018.23(3):201-209.Lisa K Stamp, Tony R Merriman, Jasvinder A Singh. Expert opinion on emerging urate-lowering therapies. Expert Opin Emerg Drugs. 2018.23(3):201-209.Kimura K., Hosoya T., Uchida S., Inaba M., Makino H., Maruyama S., Ito S., Yamamoto T., Tomino Y., Ohno I., Shibagaki Y., Iimuro S., Imai N., Kuwabara M., Hayakawa H., Ohtsu H., Ohashi Y. FEATHER Study Investigators. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis 72: 798 – 810, 2018.Kimura K., Hosoya T., Uchida S., Inaba M., Makino H., Maruyama S., Ito S., Yamamoto T., Tomino Y., Ohno I., Shibagaki Y., Iimuro S., Imai N., Kuwabara M., Hayakawa H., Ohtsu H., Ohashi Y. FEATHER Study Investigators. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis 72: 798 – 810, 2018.Kojima S., Matsui K., Hiramitsu S., Hisatome I., Waki M., Uchiyama K., Yokota N., Tokutake E., Wakasa Y., Jinnouchi H., Kakuda H., Hayashi T., Kawai N., Mor H., Sugawara M., Ohya Y., Kimura K., Saito Y., Ogawa H. Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study. Eur Heart J 40: 1778 – 1786, 2019.Kojima S., Matsui K., Hiramitsu S., Hisatome I., Waki M., Uchiyama K., Yokota N., Tokutake E., Wakasa Y., Jinnouchi H., Kakuda H., Hayashi T., Kawai N., Mor H., Sugawara M., Ohya Y., Kimura K., Saito Y., Ogawa H. Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study. Eur Heart J 40: 1778 – 1786, 2019.Ma G., Wang G., Xiao D., Teng W., Hui X., Ma G. Meta-analysis on allopurinol preventive intervention on contrast-induced acute kidney injury with random controlled trials: PRISMA. Medicine (Baltimore) 98: e15962, 2019.Ma G., Wang G., Xiao D., Teng W., Hui X., Ma G. Meta-analysis on allopurinol preventive intervention on contrast-induced acute kidney injury with random controlled trials: PRISMA. Medicine (Baltimore) 98: e15962, 2019.Pascart T., Richette P. Investigational drugs for hyper- uricemia, an update on recent developments. Expert Opin Investig Drugs. 2018 May;27(5):437-444.Pascart T., Richette P. Investigational drugs for hyper- uricemia, an update on recent developments. Expert Opin Investig Drugs. 2018 May;27(5):437-444.

The authors declare that there are no conflicts of interest present.